Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Abraham Tzou"'
Autor:
Nathan Wan, David Weinberg, Tzu-Yu Liu, Katherine Niehaus, Eric A. Ariazi, Daniel Delubac, Ajay Kannan, Brandon White, Mitch Bailey, Marvin Bertin, Nathan Boley, Derek Bowen, James Cregg, Adam M. Drake, Riley Ennis, Signe Fransen, Erik Gafni, Loren Hansen, Yaping Liu, Gabriel L. Otte, Jennifer Pecson, Brandon Rice, Gabriel E. Sanderson, Aarushi Sharma, John St. John, Catherina Tang, Abraham Tzou, Leilani Young, Girish Putcha, Imran S. Haque
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Blood-based methods using cell-free DNA (cfDNA) are under development as an alternative to existing screening tests. However, early-stage detection of cancer using tumor-derived cfDNA has proven challenging because of the small pr
Externí odkaz:
https://doaj.org/article/fe732f6285b646618c64630c5a91ae05
Autor:
Reena Philip, Richard Pazdur, Geoffrey Kim, Amy E. McKee, Gideon M. Blumenthal, Abraham Tzou, Julia A. Beaver
Supplementary Table S1: Complex Signature Oncology In Vitro Diagnostic Devices
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08bf59ad31e66a30d44e3bd5e085b067
https://doi.org/10.1158/1078-0432.22462790
https://doi.org/10.1158/1078-0432.22462790
Autor:
Reena Philip, Richard Pazdur, Geoffrey Kim, Amy E. McKee, Gideon M. Blumenthal, Abraham Tzou, Julia A. Beaver
As technologies evolve, and diagnostics move from detection of single biomarkers toward complex signatures, an increase in the clinical use and regulatory submission of complex signatures is anticipated. However, to date, no complex signatures have b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba0f51102e805bb033991a39c86ad42e
https://doi.org/10.1158/1078-0432.c.6525209.v1
https://doi.org/10.1158/1078-0432.c.6525209.v1
Autor:
Abraham Tzou, Jennifer Pecson, Tzu-Yu Liu, Signe Fransen, John St. John, David E. Weinberg, Riley Ennis, Yaping Liu, Brandon J. Rice, Daniel Delubac, Nathan Boley, Marvin Bertin, Katherine E. Niehaus, Leilani Young, Aarushi Sharma, Girish Putcha, Adam Drake, James Cregg, Erik Gafni, Nathan Wan, Catherina Tang, Derek Bowen, Brandon White, Imran S. Haque, Ajay Kannan, Mitch Bailey, Gabriel E. Sanderson, Eric A. Ariazi, Gabriel Otte, Loren Hansen
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
BackgroundBlood-based methods using cell-free DNA (cfDNA) are under development as an alternative to existing screening tests. However, early-stage detection of cancer using tumor-derived cfDNA has proven challenging because of the small proportion o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ac7ac8fea1c37b4c91bf798c0a4eff
https://pubmed.ncbi.nlm.nih.gov/31443703
https://pubmed.ncbi.nlm.nih.gov/31443703
Autor:
Julia A. Beaver, Geoffrey Kim, Amy E. McKee, Richard Pazdur, Gideon M. Blumenthal, Abraham Tzou, Reena Philip
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(6)
As technologies evolve, and diagnostics move from detection of single biomarkers toward complex signatures, an increase in the clinical use and regulatory submission of complex signatures is anticipated. However, to date, no complex signatures have b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdb219ca199332cef6ae32bf182123fb
https://pubmed.ncbi.nlm.nih.gov/27993967
https://pubmed.ncbi.nlm.nih.gov/27993967
Autor:
Eric A. Ariazi, Gabriel Otte, Singer Michael, Jonathan Berliner, John Dulin, Riley Ennis, David H. Weinberg, Adam Drake, Girish Putcha, Brandon White, Imran S. Haque, Abraham Tzou, Jennifer Pecson, Daniel Delubac, Aarushi Sharma, Jill Waters, Corey Schaninger, Katherine E. Niehaus, Erik Gafni
Publikováno v:
Cancer Research. 78:2227-2227
Introduction: Blood-based tests hold great promise as cancer diagnostics but until now have largely been restricted to the analysis of a single class of molecules (eg, circulating tumor DNA, platelet mRNA, circulating proteins). The ability to analyz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d8b66c02b392b656b0c456e0621bc53
https://doi.org/10.1158/1538-7445.am2018-2227
https://doi.org/10.1158/1538-7445.am2018-2227
Autor:
Amna Ibrahim, Elimika Pfuma, Gaetan Ladouceur, Hui Zhang, Anne Marie Russell, Haw-Jyh Chiu, Todd R. Palmby, Rajeshwari Sridhara, Thomas Gwise, Rajesh Venugopal, Shenghui Tang, Amy E. McKee, Abraham Tzou, Liang Zhao, Eunice Y. Lee, Reena Philip, Tiffany K. Ricks, Richard Pazdur, Gwynn Ison, Qi Liu, Hongshan Li, Geoffrey Kim
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(19)
On December 19, 2014, the FDA approved olaparib capsules (Lynparza; AstraZeneca) for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f00b273fcfd473bf4da5f5880016b82e
https://pubmed.ncbi.nlm.nih.gov/26187614
https://pubmed.ncbi.nlm.nih.gov/26187614
Autor:
Andreas Rosenwald, M. Sathyamoorthy, Roland Martin, P. Mattar, Joseph A. Frank, Klaus-Peter Wandinger, S. Stürzebecher, Henry F. McFarland, Abraham Tzou, Louis M. Staudt
Publikováno v:
Brain. 126:1419-1429
Autoimmune diseases such as multiple sclerosis are characterized by complex genetic traits and pathomechanisms that translate into clinical heterogeneity. This wide heterogeneity of multiple sclerosis as well as different biological responses to immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d107f8f8e5901784e7a7c0ae58535773
https://doi.org/10.1093/brain/awg147
https://doi.org/10.1093/brain/awg147
Autor:
Silva Markovic-Plese, Clemencia Pinilla, Laurie Ward Whitney, Richard Simon, Yingdong Zhao, Roland Martin, Abraham Tzou, William E. Biddison, Bruno Gran, Bernhard Hemmer
Publikováno v:
The Journal of Immunology. 167:2130-2141
The interaction of TCRs with MHC peptide ligands can be highly flexible, so that many different peptides are recognized by the same TCR in the context of a single restriction element. We provide a quantitative description of such interactions, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ed2d9f08cffffd8425c2b021135228a
https://doi.org/10.4049/jimmunol.167.4.2130
https://doi.org/10.4049/jimmunol.167.4.2130
Autor:
Jeannick Pascal, Henry F. McFarland, Takayuki Kondo, Richard A. Houghten, Abraham Tzou, Bruno Gran, Clemencia Pinilla, Irene Cortese, Bernhard Hemmer, Roland Martin
Publikováno v:
International Immunology. 12:375-383
CD4(+) T lymphocytes usually recognize peptides of 12-16 amino acids in the context of HLA class II molecules. We have recently used synthetic peptide combinatorial libraries to dissect in detail antigen recognition by autoreactive CD4(+) T cell clon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6b6a2462512bdeb2b0f174f3ca561fc
https://doi.org/10.1093/intimm/12.3.375
https://doi.org/10.1093/intimm/12.3.375